Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions [4]

British Journal of Haematology

Volumn 119, Issue 2, 2002, Pages 576-577

  Jones, S G ^a   Dolan, G ^a   Lengyel, K ^a   Myers, B ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Creatinine; Hypocalcaemia; Thalidomide; Zoledronic acid; Zometa

Indexed keywords

BENDROFLUMETHIAZIDE; CALCITRIOL; CALCIUM; CREATININE; CYCLOPHOSPHAMIDE; DICLOFENAC; ELECTROLYTE; GLUCONATE CALCIUM; IMMUNOGLOBULIN G; INFUSION FLUID; MELPHALAN; PAMIDRONIC ACID; PARAPROTEIN; THALIDOMIDE; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; AGED; CALCIUM BLOOD LEVEL; CASE REPORT; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; ECHOGRAPHY; FEMALE; HUMAN; HYPOCALCEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LETTER; MALE; MUSCLE WEAKNESS; MYELOMA; PARESTHESIA; PRIORITY JOURNAL; TREMOR;

EID: 0036441362     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03835_4.x     Document Type: Letter

References (4)

1. Berenson, J.R., Rosen, L.S., Howell, A., Porter, L., Coleman, R.E., Morley, W., Dreicer, R., Kuross, S.A., Lipton, A. & Seaman, J.J. (2001) Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer, 91, 1191-1200.
2. Green, J.R., Muller, K. & Jaeggi, K.A. (1994) Preclinical pharmacology of CGP42′446. A new, potent, heterocyclic bisphosphonate compound. Journal of Bone Mineral Research, 9, 745-751.
3. Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H.D., Yunus, F., Bell, R., Body, J., Quebe-Fehling, E. & Seaman, J. (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcaemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. Journal of Clinical Oncology, 19, 558-567.
4. Rosen, L.S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M., Coleman, R.E., Reitsma, D.J., Seaman, J.J., Chen, B. & Ambros, Y. (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer Journal, 7, 377-387.